Cargando…
Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States
INTRODUCTION: Treatment patterns and costs were characterized among patients with overactive bladder (OAB) receiving later‐line target therapies (combination mirabegron/antimuscarinic, sacral nerve stimulation [SNS], percutaneous tibial nerve stimulation [PTNS], or onabotulinumtoxinA). METHODS: In a...
Autores principales: | Kraus, Stephen R., Shiozawa, Aki, Szabo, Shelagh M., Qian, Christina, Rogula, Basia, Hairston, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693053/ https://www.ncbi.nlm.nih.gov/pubmed/32827230 http://dx.doi.org/10.1002/nau.24474 |
Ejemplares similares
-
Cost-effectiveness of sacral nerve stimulation and percutaneous
tibial nerve stimulation for faecal incontinence
por: Hounsome, Natalia, et al.
Publicado: (2018) -
Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis
por: Lo, Chi-Wen, et al.
Publicado: (2020) -
Sacral Nerve Stimulation Through the Sacral Hiatus
por: Park, Chan Hong, et al.
Publicado: (2012) -
Treatment for overactive bladder: A meta-analysis of transcutaneous tibial nerve stimulation versus percutaneous tibial nerve stimulation
por: Yang, Ding-Yuan, et al.
Publicado: (2021) -
OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012)